Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901255 | 0.86 | NPC1 (0.33) | HPGDHCAR3HCAR2NPC1 | |
| SCHEMBL23482676 | 0.86 | NPC1 (0.33) | HPGDHCAR3HCAR2NPC1 | |
| SCHEMBL14262396 | 0.78 | NPC1 (0.53) | HPGDHCAR3HCAR2TOP2AALDH1A1 | |
| SCHEMBL25024096 | 0.77 | HPGD (0.32) | HPGDHCAR3HCAR2TOP2A | |
| SCHEMBL20159610 | 0.76 | HPGD (0.36) | HPGDHCAR3HCAR2TOP2AALDH1A1 | |
| SCHEMBL23482739 | 0.74 | NPC1 (0.39) | HCAR3NPC1TSHR | |
| SCHEMBL14262389 | 0.72 | HTT (0.44) | ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL25062347 | 0.70 | NPC1 (0.35) | NPC1 | |
| SCHEMBL22044444 | 0.69 | NPC1 (0.34) | NPC1 | |
| SCHEMBL23894100 | 0.69 | NPC1 (0.33) | HPGDHCAR3HCAR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165930-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230149502-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | disclosed |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165930-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, TEK | HPGD 4696/4885HCAR3 773/4885HCAR2 1634/4885 |
| US-20230057350-A1 | A CONJUGATE OF AN AMANITA TOXIN WITH BRANCHED LINKERS | BTN3A1, ANTXR2, CLTA | HPGD 4664/4885HCAR3 475/4885HCAR2 1090/4885 |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, CD4 | HPGD 4693/4885HCAR3 768/4885HCAR2 1603/4885 |
| US-20210369855-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | HPGD 4477/4885HCAR3 3410/4885HCAR2 1676/4885 |
| US-20230001001-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | HPGD 4477/4885HCAR3 3410/4885HCAR2 1676/4885 |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | HPGD 4839/4885HCAR3 2361/4885HCAR2 3644/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | HPGD 877/4885HCAR3 145/4885HCAR2 44/4885 |
| US-20210393790-A1 | CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE | CD4, MCL1, CCNB1 | HPGD 4477/4885HCAR3 3410/4885HCAR2 1676/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | HPGD 3960/4885HCAR3 1153/4885HCAR2 1238/4885 |
| US-20230149502-A1 | CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, TEK | HPGD 4696/4885HCAR3 773/4885HCAR2 1634/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | HPGD 3435/4885HCAR3 2331/4885HCAR2 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.